- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
Evotec SE today announced the initiation of a Phase 1 clinical trial evaluating JST-018, a cocktail of investigational monoclonal antibodies targeting orthopoxviruses, developed by its biologics CDMO subsidiary Just – Evotec Biologics under the U.S. Department of War’s Accelerated Antibodies Program.
Evotec SE today announced the initiation of a Phase 1 clinical trial evaluating JST-018, a cocktail of investigational monoclonal antibodies targeting orthopoxviruses, developed by its biologics CDMO subsidiary Just – Evotec Biologics under the U.S. Department of War’s Accelerated Antibodies Program.
Evotec SE and Plectonic Biotech today announced a research collaboration to explore a novel immunotherapy approach for solid tumors. The collaboration addresses key challenges that have so far limited the successful application of traditional T cell engager therapies in solid tumors by combining Plectonic’s programmable LOGIBODY® technology with Evotec’s proprietary BiTco platform.
Evotec SE and Plectonic Biotech today announced a research collaboration to explore a novel immunotherapy approach for solid tumors. The collaboration addresses key challenges that have so far limited the successful application of traditional T cell engager therapies in solid tumors by combining Plectonic’s programmable LOGIBODY® technology with Evotec’s proprietary BiTco platform.
Evotec SE today announced financial results for the second quarter and first half of 2026 and confirmed its updated full-year 2026 outlook.
Evotec SE today announced financial results for the second quarter and first half of 2026 and confirmed its updated full-year 2026 outlook.
Evotec SE today announced that it has entered a strategic R&D collaboration with Odyssey Therapeutics, Inc. to discover potential new treatments in autoimmune and inflammatory diseases.
Evotec SE today announced that it has entered a strategic R&D collaboration with Odyssey Therapeutics, Inc. to discover potential new treatments in autoimmune and inflammatory diseases.
Niagen Bioscience, Inc., the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it has selected Evotec, a global life science company specializing in drug discovery and development, as a contract research organization to support the advancement of NB4168. The work will be conducted in collaboration with NAD Pharmaceuticals Corp., Niagen Bioscience’s wholly owned subsidiary focused on developing therapies for accelerated aging and rare genetic diseases.
Niagen Bioscience, Inc., the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it has selected Evotec, a global life science company specializing in drug discovery and development, as a contract research organization to support the advancement of NB4168. The work will be conducted in collaboration with NAD Pharmaceuticals Corp., Niagen Bioscience’s wholly owned subsidiary focused on developing therapies for accelerated aging and rare genetic diseases.